BioCentury
ARTICLE | Politics & Policy

ICER announces preliminary 2019 topics

August 3, 2018 10:10 PM UTC

The Institute for Clinical and Economic Review (ICER) released Thursday a preliminary list of drugs and other healthcare interventions that it may review in 2019. ICER's selection criteria include the projected timing and likelihood of FDA approval and whether a review of the evidence would suggest specific actions for payers, physicians, patients and policymakers to improve clinical practice.

ICER lists 15 drug candidates for consideration next year, including two Phase III peanut allergy therapies -- AR101 from Aimmune Therapeutics Inc. (NASDAQ:AIMT) and Viaskin Peanut (DBV-712) from DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT); and two next-generation sphingosine 1-phosphate receptor 1 (S1PR1; S1P1; EDG1) agonists for multiple sclerosis -- siponimod (BAF312) from Novartis AG (NYSE:NVS; SIX:NOVN) and ozanimod (RPC1063) from Celgene Corp. (NASDAQ:CELG)...